0001209191-20-052763.txt : 20201001
0001209191-20-052763.hdr.sgml : 20201001
20201001192359
ACCESSION NUMBER: 0001209191-20-052763
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201001
FILED AS OF DATE: 20201001
DATE AS OF CHANGE: 20201001
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: UBS Oncology Impact Fund L.P.
CENTRAL INDEX KEY: 0001691428
STATE OF INCORPORATION: E9
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39575
FILM NUMBER: 201217636
BUSINESS ADDRESS:
STREET 1: 450 KENDALL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-425-9200
MAIL ADDRESS:
STREET 1: 450 KENDALL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Oncology Impact Fund (Cayman) Management L.P.
CENTRAL INDEX KEY: 0001721036
STATE OF INCORPORATION: E9
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39575
FILM NUMBER: 201217637
BUSINESS ADDRESS:
STREET 1: 450 KENDALL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 6174259200
MAIL ADDRESS:
STREET 1: 450 KENDALL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MPM Oncology Impact Management GP LLC
CENTRAL INDEX KEY: 0001721035
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39575
FILM NUMBER: 201217638
BUSINESS ADDRESS:
STREET 1: 450 KENDALL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 6174259200
MAIL ADDRESS:
STREET 1: 450 KENDALL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MPM Oncology Impact Management LP
CENTRAL INDEX KEY: 0001687078
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39575
FILM NUMBER: 201217639
BUSINESS ADDRESS:
STREET 1: 450 KENDALL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 6174259200
MAIL ADDRESS:
STREET 1: 450 KENDALL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Oncorus, Inc.
CENTRAL INDEX KEY: 0001671818
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 473779757
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 450 KENDALL STREET
STREET 2: 5TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-425-9200
MAIL ADDRESS:
STREET 1: 450 KENDALL STREET
STREET 2: 5TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
3
1
doc3.xml
FORM 3 SUBMISSION
X0206
3
2020-10-01
0
0001671818
Oncorus, Inc.
ONCR
0001691428
UBS Oncology Impact Fund L.P.
UBS TRUSTEES (CAYMAN) LTD
5TH FL CAYMAN CORP CENTER 27 HOSPITAL
GEORGE TOWN
E9
KY1-1106
CAYMAN ISLANDS
0
0
1
0
0001721036
Oncology Impact Fund (Cayman) Management L.P.
UBS TRUSTEES (CAYMAN) LTD
5TH FL CAYMAN CORP CENTER 27 HOSPITAL
GEORGE TOWN
E9
KY1-1106
CAYMAN ISLANDS
0
0
1
0
0001721035
MPM Oncology Impact Management GP LLC
C/O MPM ASSET MANAGEMENT LLC
450 KENDALL STREET
CAMBRIDGE
MA
02142
0
0
1
0
0001687078
MPM Oncology Impact Management LP
C/O MPM ASSET MANAGEMENT LLC
450 KENDALL STREET
CAMBRIDGE
MA
02142
0
0
1
0
Series A-1 Preferred Stock
Common Stock
1525348
D
Series B Preferred Stock
Common Stock
700453
D
Warrant (right to buy)
1.21
2031-03-31
Common Stock
27146
D
Each share of Series A-1 Preferred and Series B Preferred Stock is convertible at any time at the option of the holder, without payment of
additional consideration, into Common Stock, on a one-for-one basis, has no expiration date and will automatically convert into shares of Common
Stock upon the closing of the Issuer's initial public offering.
The reported securities are held in the account of UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing member of Oncology GP LLC.
The Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein.
Immediately exercisable.
s/ Ansbert Gadicke, managing director of MPM Oncology Impact Management GP LLC, the general partner of MPM Oncology Impact Management LP, the general partner of Oncology Impact Fund (Cayman) Management L.P., the GP of UBS Oncology Impact Fund L.P
2020-10-01
/s/ Ansbert Gadicke, managing director of MPM Oncology Impact Management GP LLC, the general partner of MPM Oncology Impact Management LP, the general partner of Oncology Impact Fund (Cayman) Management L.P.
2020-10-01
/s/ Ansbert Gadicke, managing director of MPM Oncology Impact Management GP LLC
2020-10-01
/s/ Ansbert Gadicke, managing director of MPM Oncology Impact Management GP LLC, the general partner of MPM Oncology Impact Management LP
2020-10-01